Sept. 10, 2019 Price forecast | 2 weeks: 0.46% | 1 month: 1.02% | 3 months: 0.44%


REGN stock forecast

Our latest prediction for Regeneron Pharmaceuticals, Inc.'s stock price was made on the Sept. 10, 2019 when the stock price was at 283.72$.

In the short term (2weeks), REGN's stock price should outperform the market by 0.46%. During that period the price should oscillate between -3.98% and +5.06%.

In the medium term (3months), REGN's stock price should outperform the market by 0.44%. During that period the price should oscillate between -9.52% and +13.27%.


About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

At the moment the company generates 7237M USD in revenues.

On its last earning announcement, the company reported a profit of 18.01$ per share.

The book value per share is 66.51$

Regeneron Pharmaceuticals, Inc. website


Three months stock forecastSept. 10, 2019


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
7237M 92.30% 2140M 29.60% 2069M 18.01 - - 115M 66.51 2267M -361M 1906M